Shots:
- Endo to acquire all the outstanding shares of BioSpecifics for $88.50/ share in cash, making a total deal value of $540M. The transaction is expected to close in late 2020 while Endo expects to fund the transaction with cash on hand
- BioSpecifics receives a royalty stream related to Endo’s collagenase-based therapies, which include Xiaflex for Dupuytren’s contracture and Peyronie’s disease, and Qwo for cellulite, which is expected to be launched by Endo in spring 2021
- Endo’s acquisition subsidiary will be merged into BioSpecifics, and the remaining shares of BioSpecifics will be canceled and converted into the right to receive the same consideration payable pursuant to the tender offer
Click here to read full press release/ article | Ref: PRNewswire | Image: Seeking Alpha
The post Endo to Acquire BioSpecifics for ~ 0M first appeared on PharmaShots.
